Reported Late Monday Feb.27, South Korea's GC Biopharma, Announced Today That It Has Signed An Asset Purchase Agreement With Catalyst Biosciences To Acquire 3 Programs Related To The Orphan Hematology Disorders; No Financial Terms Disclosed
Reported Late Monday Feb.27, South Korea's GC Biopharma, Announced Today That It Has Signed An Asset Purchase Agreement With Catalyst Biosciences To Acquire 3 Programs Related To The Orphan Hematology Disorders; No Financial Terms Disclosed
GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ:CBIO) to acquire 3 programs related to the orphan hematology disorders.
韩国领先的生物制药产品提供商GC Biopharma Corp.（006280.KS）今天宣布，它已与Catalyst Biosciences（纳斯达克股票代码：CBIO）签署了资产购买协议，收购了3个与孤儿血液病有关的项目。
This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development.
该协议将为GC Biopharma 3项目带来，包括 “Marzeptacog alfa（MarzaA）”，这是一种已为3期临床阶段开发做好准备的工程因子ViiA。
In its previous clinical development trials, "MarzAA" demonstrated efficacy and safety as a treatment for rare bleeding disorders. More significantly, "MarzAA", unlike majority of existing therapeutics, is delivered by subcutaneous injection, making it more convenient to administer and less burdensome for the patients, who require life-long treatment.
在先前的临床开发试验中，“MarZaA” 显示出治疗罕见出血性疾病的疗效和安全性。更重要的是，与大多数现有疗法不同，“marZaA” 是通过皮下注射提供的，这使得给药更方便，也减轻了需要终身治疗的患者的负担。
It is GC Biopharma's plan to continue development of the asset in pursuit of launching a first-in-class novel drug that will pave the way for the company to make inroads into the global markets, including the US and other advanced markets.
GC Biopharma计划继续开发该资产，以期推出一款同类首创的新药，这将为该公司进入包括美国和其他发达市场在内的全球市场铺平道路。
Since its founding, GC Biopharma has worked on providing better therapeutic options for hemophilia, one of the most well-known rare bleeding disorders. "Green Mono", a plasma-derived FVIII drug, and "GreenGene F", a recombinant FVIII drug are hemophilia drugs exclusively developed by the company. GC Biopharma is keen to develop new drugs for various orphan disorders not only through its in-house R&D capabilities, but also through leveraging its strength in managing external partnerships.
自成立以来，GC Biopharma一直致力于为血友病提供更好的治疗选择，血友病是最著名的罕见出血性疾病之一。血浆衍生的FVIII药物 “Green Mono” 和重组FVIII药物 “GreenGene F” 是该公司独家开发的血友病药物。GC Biopharma热衷于开发针对各种孤儿病的新药，这不仅是通过其内部研发能力，还包括利用其在管理外部合作伙伴关系方面的优势。
Nassim Usman, Ph.D., President and CEO of Catalyst Biosciences, said, "We are pleased that GC Biopharma has purchased our hemophilia assets and will continue their clinical development to potentially bring new transformative treatments for several bleeding disorders".
Catalyst Biosciences总裁兼首席执行官纳西姆·乌斯曼博士说：“我们很高兴GC Biopharma收购了我们的血友病资产，并将继续进行临床开发，有可能为几种出血性疾病带来新的变革性治疗方法”。
"We will extend our continuous global endeavour to improve therapeutic treatments for patients suffering from many orphan disorders, including rare bleeding disorders", said Eun-Chul Huh, Ph.D., President of GC Biopharma.
GC Biopharma总裁Eun-Chul Huh博士说：“我们将继续在全球范围内努力，改善患有许多孤儿疾病（包括罕见出血性疾病）的患者的治疗方法。”
RM Global Partners LLC acted as GC Biopharma's advisors for this transaction.
RM Global Partners LLC担任GC Biopharma在这笔交易中的顾问